Orexo AB (ORXOY)
3.00
0.00 (0.00%)
USD |
OTCM |
Dec 15, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 104.12M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 153.2% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 91.51% |
Profile
| Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. It operates through the following segments: US Commercial and HQ and Pipelines. The US Commercial segment focuses on marketing and distributing a prescription medication used for opioid dependence treatment in the US. The HQ and Pipeline segment focuses in the out-licensed pharmaceuticals and costs for research and development, business development, global regulatory, and supply chain. The company was founded by Thomas Lundqvist on November 18, 1994 and is headquartered in Uppsala, Sweden. |
| URL | http://www.orexo.se |
| Investor Relations URL | N/A |
| HQ State/Province | Uppsala |
| Sector | |
| Industry | |
| Next Earnings Release | Feb. 05, 2026 |
| Last Earnings Release | Oct. 23, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. It operates through the following segments: US Commercial and HQ and Pipelines. The US Commercial segment focuses on marketing and distributing a prescription medication used for opioid dependence treatment in the US. The HQ and Pipeline segment focuses in the out-licensed pharmaceuticals and costs for research and development, business development, global regulatory, and supply chain. The company was founded by Thomas Lundqvist on November 18, 1994 and is headquartered in Uppsala, Sweden. |
| URL | http://www.orexo.se |
| Investor Relations URL | N/A |
| HQ State/Province | Uppsala |
| Sector | |
| Industry | |
| Next Earnings Release | Feb. 05, 2026 |
| Last Earnings Release | Oct. 23, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |